Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human BRCA1 Antikörper:
anti-Mouse (Murine) BRCA1 Antikörper:
anti-Rat (Rattus) BRCA1 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal BRCA1 Primary Antibody für ChIP, ICC - ABIN450350
Arizti, Fang, Park, Yin, Solomon, Ouchi, Aaronson, Lee: Tumor suppressor p53 is required to modulate BRCA1 expression. in Molecular and cellular biology 2000
Show all 9 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für IHC (p), IP - ABIN445490
Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001
Show all 8 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für FACS, WB - ABIN151683
Zaugg, Su, Reilly, Moolani, Cheung, Hakem, Hirao, Liu, Elledge, Mak: Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. in Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 7 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für IHC - ABIN965696
Kim, Xu, Kastan: Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. in Genes & development 2002
Show all 5 Pubmed References
Human BRCA1 Primary Antibody für IHC - ABIN965694
Arlt, Xu, Durkin, Casper, Kastan, Glover: BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. in Molecular and cellular biology 2004
Show all 5 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für CyTOF, FACS - ABIN152030
Okada, Ouchi: Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. in The Journal of biological chemistry 2003
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für ICC, FACS - ABIN152032
Martin, Nahas, Tunuguntla, Fike, Gatti: Assessing 'radiosensitivity' with kinetic profiles of γ-H2AX, 53BP1 and BRCA1 foci. in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für ChIP, ICC - ABIN151868
Li, Ting, Zheng, Chen, Ziv, Shiloh, Lee, Lee: Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. in Nature 2000
Show all 3 Pubmed References
Polyclonal BRCA1 Primary Antibody für IF - ABIN4948304
Scully, Livingston: In search of the tumour-suppressor functions of BRCA1 and BRCA2. in Nature 2000
Show all 3 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für IP, PLA - ABIN151492
Rusin, Zajkowicz, Butkiewicz: Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. in Mechanisms of ageing and development 2009
Show all 2 Pubmed References
We demonstrate that homologous recombination deficiency (HRD)mutation signatures may offer clinically relevant information independently of BRCA1/2 mutation status and hope this work will guide the development of clinical trials
Overall, 65/648 (10%) study participants were BRCA1/2 mutation carriers.
BRCA1*R1699Q confers an intermediate risk for breast cancer and ovarian cancer.
patient-derived xenografts capture the molecular and phenotypic heterogeneity of triple-negative breast cancer . Here we show that PARP inhibition can have activity beyond germline BRCA1/2 altered tumors, causing regression in a variety of molecular subtypes. These models represent an opportunity for the discovery of rational combinations with targeted therapies and predictive biomarkers
Putative BRCA1/2 reversion mutations can be detected by cfDNA sequencing analysis in patients with ovarian and breast cancer. Our findings warrant further investigation of cfDNA sequencing to identify putative BRCA1/2 reversion mutations and to aid the selection of patients for PARP (zeige COL11A2 Antikörper) inhibition therapy
The frequency of the BRCA1 5382insC mutation in ovarian cancer patients from Ukraine
Tumor suppressor functions of MCPH1/BRIT1 (zeige MCPH1 Antikörper) and BRCA1; links with the inactivation of the functional form of hTERT and the activation of dominant negative splice variants of hTERT.
Our results highlight complexity in BRCA1 transcript structure that has not been described previously. This finding has key implications for predicting the translation frame of splicing transcripts, important for interpreting the clinical significance of spliceogenic variants.
The mechanism by which RAD52 depletion causes synthetic lethality in BRCA1 mutant cancer cells depends on the 5' endonuclease EEPD1, which normally functions to cleave stressed replication forks to initiate HR repair.
Molecular subtype triple negative breast cancer was strongly associated with BRCA1 mutation in patients from Murcia (south-eastern Spain).
Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.
The gene-specific SNP marker analysis showed a significant association of BRCA1 C28300A with milk somatic cell scores.
Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents.These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress.
In general, OC use, childbearing and breastfeeding do not differ between BRCA1/2 carriers and non-carriers with ovarian cancer. However, the effects of tubal ligation may differ between BRCA1 carriers and non-carriers.
Consensus-based recombinant adeno-associated virus-BRCA1 knock out virus vectors failed to induce BRCA1 knockout in Gottingen fibroblasts.
Recent work in a TP53(-/-)BRCA1-mutant murine breast cancer model indicates that double blockade with two immune checkpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival after DNA damaging chemotherapy, whereas single blockade does not
Data indicate the importance of breast cancer 1 protein (BRCA1)/breast cancer 2 protein (BRCA2 (zeige BRCA2 Antikörper)) function in cranial neural crest cells (CNCCs) during craniofacial skeletal formation.
ATM (zeige ATM Antikörper) has a role in homology-directed repair (HDR (zeige GATA3 Antikörper)) independent of the BRCA1-53BP1 (zeige TP53BP1 Antikörper) antagonism; its HDR (zeige GATA3 Antikörper) function can become critical in certain contexts
BRCA1, but not BRCA2, suppresses the formation of tandem duplications at a site-specific chromosomal replication fork barrier imposed by the binding of Tus proteins to an array of Ter sites. BRCA1 has no equivalent role at chromosomal double-stranded DNA breaks, indicating that tandem duplications form specifically at stalled forks.
Loss of p16INK4 protein (p16) transforms breast cancer 1 (Brca1)-deficient mammary epithelial cell (MEC (zeige CCL28 Antikörper)) and induces mammary tumors.
Brca1 is necessary for hematopoietic stem cells maintenance and normal hematopoiesis and that distinct mutations lead to different degrees of hematopoietic dysfunction.
TGFbeta (zeige TGFB1 Antikörper) stabilized the abundance of BRCA1 by reducing the abundance of microRNA-182 (miR (zeige MLXIP Antikörper)-182). Ectopic expression of BRCA1 or antagonism of miR (zeige MLXIP Antikörper)-182 in cultured TGFbeta (zeige TGFB1 Antikörper)-deficient mammary epithelial cells restored luminal lineage commitment.
BRCA1 inactivation can increase expression of miR (zeige MLXIP Antikörper)-155, contributing to cardiac hypertrophy. And Rev produces their beneficial effects partially by down-regulating miR (zeige MLXIP Antikörper)-155 expression, which might be a novel strategy for treatment of cardiac hypertrophy.
both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells express a new gene domain-less (RING-less) BRCA1 protein that mediated resistance to homologous recombination deficient-targeted therapies
Genomic instability can be rescued by deletion of Trp53bp1 (zeige TP53BP1 Antikörper), encoding the DNA damage response factor 53BP1 (zeige TP53BP1 Antikörper); mice expressing RING-less BRCA1 do not show an increased susceptibility to tumors in the absence of 53BP1 (zeige TP53BP1 Antikörper); Genomic instability in cells expressing RING-less BRCA1 correlates with loss of BARD1 (zeige BARD1 Antikörper) and a defect in restart of replication forks after hydroxyurea treatment
MRN (Mre11 (zeige MRE11A Antikörper), Rad50 (zeige RAD50 Antikörper), and Nbs1 (zeige NLRP2 Antikörper)) complex, CtIP (zeige RBBP8 Antikörper), and BRCA1 are required for both the removal of Top2 (zeige TOP2 Antikörper)-DNA adducts and the subsequent resection of Top2 (zeige TOP2 Antikörper)-adducted DSB ends.
BRCA1-dependent helicase (zeige DNA2 Antikörper) unloading is a critical, early event in DNA interstrand crosslink repair.
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.
BRCA1/BRCA2-containing complex, subunit 1
, RING finger protein 53
, breast and ovarian cancer susceptibility protein 1
, breast and ovarian cancer sususceptibility protein 1
, breast cancer type 1 susceptibility protein
, protein phosphatase 1, regulatory subunit 53
, BRCA1 homologue
, breast cancer type 1 susceptibility protein homolog
, breast cancer 1, early onset
, BRCA1 homolog
, breast and ovarian cancer susceptibility protein
, breast cancer associated 1